Relmada Therapeutics, Inc. RLMD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -48.8%+45.2pp | -94%+103pp | -196.8%-21.7pp | -175.1%-14.9pp | -160.3%-27.9pp | |
| Liquidity | ||||||
| Current ratio | 18.3×+3.6× | 14.6×+11.8× | 2.9×-1.2× | 4.1×-1.2× | 5.3×+0.8× | |
| Per Share | ||||||
| Book value per share | $2.53+15.3% | $2.19+668% | $0.29-40.6% | $0.48-34.9% | $0.74-37.3% | |
| Valuation | ||||||
| Market capitalization | $677.17M+2,907% | $354.2M+431% | $66.72M+240% | $19.65M+119% | $8.96M-42.9% | |
| Price / book | 3.1×+2.1× | 4.1×-3.0× | 7×+5.8× | 1.2×+0.8× | 0.4×0.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Relmada Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Relmada Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.